Floatz logo

Bms-907351

Metastatic Neuroendocrine Neoplasm

Fox Chase Cancer CenterPhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
95/ 100

Competitive context

61 Active assets in the Metastatic Neuroendocrine Neoplasm cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
ITM Solucin GmbH
Phase 3BB
Irinotecan
First Affiliated Hospital Xi'an Jiaotong University
Phase 4BB
Eloxatin
ITM Solucin GmbH
Phase 3BB
Pasireotide
RECORDATI GROUP
Phase 4BB
Everolimus
Exelixis
Phase 3BB

View all 50 →

Same molecule, other indications

Bms-907351 is also rated in:

renal carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
castration-resistant prostate carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
non-small cell lung carcinomaDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →